| KREJČÍ, Marta, Zdeněk ADAM, Tomáš BÜCHLER, Andrea KŘIVANOVÁ, Luděk POUR, Lenka ZAHRADOVÁ, Michal HOLÁNEK, Viera SANDECKÁ, Jiří MAYER, Jiří VORLÍČEK and Roman HÁJEK. Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma (Konsolidace léčby melfalanem 100 mg/m2 s novými léky pro pacienty s mnohočetným myelomem v náhlé progresi). Annals of hematology. Germany: Springer, 2010, vol. 89, No 5, p. 483-487. ISSN 0939-5555. |
Other formats:
BibTeX
LaTeX
RIS
@article{868006,
author = {Krejčí, Marta and Adam, Zdeněk and Büchler, Tomáš and Křivanová, Andrea and Pour, Luděk and Zahradová, Lenka and Holánek, Michal and Sandecká, Viera and Mayer, Jiří and Vorlíček, Jiří and Hájek, Roman},
article_location = {Germany},
article_number = {5},
keywords = {multiple myeloma; fuminant progression; melphalan},
language = {eng},
issn = {0939-5555},
journal = {Annals of hematology},
title = {Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma},
volume = {89},
year = {2010}
}
TY - JOUR
ID - 868006
AU - Krejčí, Marta - Adam, Zdeněk - Büchler, Tomáš - Křivanová, Andrea - Pour, Luděk - Zahradová, Lenka - Holánek, Michal - Sandecká, Viera - Mayer, Jiří - Vorlíček, Jiří - Hájek, Roman
PY - 2010
TI - Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma
JF - Annals of hematology
VL - 89
IS - 5
SP - 483-487
EP - 483-487
PB - Springer
SN - 09395555
KW - multiple myeloma
KW - fuminant progression
KW - melphalan
N2 - Patients with fulminant progression of multiple myeloma after autologous stem cell transplantation (ASCT) have poor prognosis. Pancytopenia, extramedullary disease, and/or renal impairment are often present, and treatment options are limited. We have retrospectively evaluated 31 pts with FPG of MM after ASCT who were treated upfront salvage therapy with melphalan followed by PBSC support and consolidation therapy using regimens containing thalidomide or bortezomib.Treatment with upfront MEL 100 followed by a thalidomide or bortezomibbased regimen can prolong overall survival to more than 12 months in 33% of pts with fulminant progression of MM.
ER -
KREJČÍ, Marta, Zdeněk ADAM, Tomáš BÜCHLER, Andrea KŘIVANOVÁ, Luděk POUR, Lenka ZAHRADOVÁ, Michal HOLÁNEK, Viera SANDECKÁ, Jiří MAYER, Jiří VORLÍČEK and Roman HÁJEK. Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma (Konsolidace léčby melfalanem 100 mg/m2 s novými léky pro pacienty s mnohočetným myelomem v náhlé progresi). \textit{Annals of hematology}. Germany: Springer, 2010, vol.~89, No~5, p.~483-487. ISSN~0939-5555.
|
